BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 16531926)

  • 1. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study.
    Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
    Nucl Med Commun; 2006 Apr; 27(4):381-6. PubMed ID: 16531926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms.
    Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
    Nucl Med Commun; 2005 May; 26(5):421-6. PubMed ID: 15838424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
    Im JH; Chung SJ; Kim JS; Lee MC
    J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Extrastriatal
    Joling M; Vriend C; van den Heuvel OA; Raijmakers PGHM; Jones PA; Berendse HW; Booij J
    J Nucl Med; 2017 Jul; 58(7):1117-1123. PubMed ID: 27856628
    [No Abstract]   [Full Text] [Related]  

  • 6. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
    Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
    J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis.
    Seppi K; Scherfler C; Donnemiller E; Virgolini I; Schocke MF; Goebel G; Mair KJ; Boesch S; Brenneis C; Wenning GK; Poewe W
    Arch Neurol; 2006 Aug; 63(8):1154-60. PubMed ID: 16908744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease.
    Varrone A; Pagani M; Salvatore E; Salmaso D; Sansone V; Amboni M; Nobili F; De Michele G; Filla A; Barone P; Pappatà S; Salvatore M
    Eur J Nucl Med Mol Imaging; 2007 Jul; 34(7):1071-81. PubMed ID: 17245531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects.
    Weng YH; Yen TC; Chen MC; Kao PF; Tzen KY; Chen RS; Wey SP; Ting G; Lu CS
    J Nucl Med; 2004 Mar; 45(3):393-401. PubMed ID: 15001678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential distribution of striatal [123I]beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography.
    Messa C; Volonté MA; Fazio F; Zito F; Carpinelli A; d'Amico A; Rizzo G; Moresco RM; Paulesu E; Franceschi M; Lucignani G
    Eur J Nucl Med; 1998 Sep; 25(9):1270-6. PubMed ID: 9724376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.
    Pirker W; Asenbaum S; Bencsits G; Prayer D; Gerschlager W; Deecke L; Brücke T
    Mov Disord; 2000 Nov; 15(6):1158-67. PubMed ID: 11104200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report.
    Di Giuda D; Calcagni ML; Totaro M; Cocciolillo F; Piano C; Soleti F; Fasano A; Cioni B; Bentivoglio AR; Giordano A
    Nucl Med Commun; 2012 Sep; 33(9):933-40. PubMed ID: 22735298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease.
    Lorberboym M; Treves TA; Melamed E; Lampl Y; Hellmann M; Djaldetti R
    Mov Disord; 2006 Apr; 21(4):510-4. PubMed ID: 16250023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
    Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
    Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
    Verstappen CC; Bloem BR; Haaxma CA; Oyen WJ; Horstink MW
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
    J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.